glp-1 receptor agonist atrial fibrillation risk Frontiers Multiple GLP-1 drugs linked to
Description
Higher dose liraglutide (3 mg) has been approved for the treatment of obesity since 2014 (Saxenda)
doi: 10.1016/j.jalz.2014.06.016 70 AthaudaDFoltynieT
diabetes 2019;68
Through a comprehensive retrospective analysis of the strength of the association, analogy, and consistency metrics of GLP-1RAs and SSIBs, we concluded that there was no evidence reasonably suggesting an association between GLP-1RAs and SSIBs
What is obesity, and why must we be concerned
Both medications are prescribed and monitored by our board-certified doctors, Dr
